Personalized cancer treatment

Israel’s GeneSort detects specific genetic mutations linked to various types of cancer. Oncologists can then adapt treatments to the patient’s specific genetic mutations, dramatically improving outcomes.  GeneSort has just been acquired by Hong Kong investment fund AID Partners for $23 million.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *